nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Methimazole—Graves' disease	0.228	0.426	CbGbCtD
Ziprasidone—CYP2D6—Methimazole—Graves' disease	0.188	0.351	CbGbCtD
Ziprasidone—CYP3A4—Methimazole—Graves' disease	0.119	0.223	CbGbCtD
Ziprasidone—DRD5—eyelid—Graves' disease	0.0493	0.448	CbGeAlD
Ziprasidone—Drug fever—Methimazole—Graves' disease	0.0326	0.136	CcSEcCtD
Ziprasidone—Drug fever—Propylthiouracil—Graves' disease	0.0277	0.116	CcSEcCtD
Ziprasidone—Lymphadenopathy—Methimazole—Graves' disease	0.00926	0.0387	CcSEcCtD
Ziprasidone—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00787	0.0329	CcSEcCtD
Ziprasidone—Renal failure acute—Propylthiouracil—Graves' disease	0.00727	0.0304	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00712	0.0297	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Methimazole—Graves' disease	0.00597	0.0249	CcSEcCtD
Ziprasidone—Jaundice—Methimazole—Graves' disease	0.00593	0.0248	CcSEcCtD
Ziprasidone—Hepatitis—Methimazole—Graves' disease	0.00546	0.0228	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00507	0.0212	CcSEcCtD
Ziprasidone—Jaundice—Propylthiouracil—Graves' disease	0.00504	0.0211	CcSEcCtD
Ziprasidone—CHRM5—eye—Graves' disease	0.00492	0.0447	CbGeAlD
Ziprasidone—Alopecia—Methimazole—Graves' disease	0.00483	0.0202	CcSEcCtD
Ziprasidone—Haemoglobin—Propylthiouracil—Graves' disease	0.00467	0.0195	CcSEcCtD
Ziprasidone—Haemorrhage—Propylthiouracil—Graves' disease	0.00465	0.0194	CcSEcCtD
Ziprasidone—Hepatitis—Propylthiouracil—Graves' disease	0.00465	0.0194	CcSEcCtD
Ziprasidone—Vertigo—Methimazole—Graves' disease	0.00427	0.0178	CcSEcCtD
Ziprasidone—Leukopenia—Methimazole—Graves' disease	0.00426	0.0178	CcSEcCtD
Ziprasidone—Alopecia—Propylthiouracil—Graves' disease	0.0041	0.0171	CcSEcCtD
Ziprasidone—H1F0—connective tissue—Graves' disease	0.00409	0.0372	CbGeAlD
Ziprasidone—Myalgia—Methimazole—Graves' disease	0.00405	0.0169	CcSEcCtD
Ziprasidone—Arthralgia—Methimazole—Graves' disease	0.00405	0.0169	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methimazole—Graves' disease	0.0038	0.0159	CcSEcCtD
Ziprasidone—Vertigo—Propylthiouracil—Graves' disease	0.00363	0.0152	CcSEcCtD
Ziprasidone—Leukopenia—Propylthiouracil—Graves' disease	0.00362	0.0151	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00354	0.0148	CcSEcCtD
Ziprasidone—Paraesthesia—Methimazole—Graves' disease	0.00349	0.0146	CcSEcCtD
Ziprasidone—Somnolence—Methimazole—Graves' disease	0.00345	0.0144	CcSEcCtD
Ziprasidone—Arthralgia—Propylthiouracil—Graves' disease	0.00344	0.0144	CcSEcCtD
Ziprasidone—Myalgia—Propylthiouracil—Graves' disease	0.00344	0.0144	CcSEcCtD
Ziprasidone—Dyspepsia—Methimazole—Graves' disease	0.00342	0.0143	CcSEcCtD
Ziprasidone—HTR1D—eye—Graves' disease	0.00329	0.0299	CbGeAlD
Ziprasidone—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00323	0.0135	CcSEcCtD
Ziprasidone—HTR1D—connective tissue—Graves' disease	0.00317	0.0288	CbGeAlD
Ziprasidone—H1F0—pituitary gland—Graves' disease	0.00315	0.0286	CbGeAlD
Ziprasidone—H1F0—adipose tissue—Graves' disease	0.00314	0.0285	CbGeAlD
Ziprasidone—Urticaria—Methimazole—Graves' disease	0.00308	0.0129	CcSEcCtD
Ziprasidone—Body temperature increased—Methimazole—Graves' disease	0.00307	0.0128	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00301	0.0126	CcSEcCtD
Ziprasidone—Paraesthesia—Propylthiouracil—Graves' disease	0.00296	0.0124	CcSEcCtD
Ziprasidone—Somnolence—Propylthiouracil—Graves' disease	0.00293	0.0123	CcSEcCtD
Ziprasidone—Dyspepsia—Propylthiouracil—Graves' disease	0.0029	0.0121	CcSEcCtD
Ziprasidone—H1F0—thyroid gland—Graves' disease	0.00271	0.0247	CbGeAlD
Ziprasidone—Urticaria—Propylthiouracil—Graves' disease	0.00262	0.0109	CcSEcCtD
Ziprasidone—Body temperature increased—Propylthiouracil—Graves' disease	0.00261	0.0109	CcSEcCtD
Ziprasidone—HTR7—connective tissue—Graves' disease	0.00252	0.0229	CbGeAlD
Ziprasidone—DRD2—eye—Graves' disease	0.00248	0.0225	CbGeAlD
Ziprasidone—Vomiting—Methimazole—Graves' disease	0.00247	0.0103	CcSEcCtD
Ziprasidone—Rash—Methimazole—Graves' disease	0.00245	0.0102	CcSEcCtD
Ziprasidone—Dermatitis—Methimazole—Graves' disease	0.00244	0.0102	CcSEcCtD
Ziprasidone—Headache—Methimazole—Graves' disease	0.00243	0.0102	CcSEcCtD
Ziprasidone—Nausea—Methimazole—Graves' disease	0.00231	0.00963	CcSEcCtD
Ziprasidone—Vomiting—Propylthiouracil—Graves' disease	0.0021	0.00876	CcSEcCtD
Ziprasidone—Rash—Propylthiouracil—Graves' disease	0.00208	0.00869	CcSEcCtD
Ziprasidone—Dermatitis—Propylthiouracil—Graves' disease	0.00208	0.00868	CcSEcCtD
Ziprasidone—Headache—Propylthiouracil—Graves' disease	0.00207	0.00863	CcSEcCtD
Ziprasidone—CHRM3—adipose tissue—Graves' disease	0.00203	0.0185	CbGeAlD
Ziprasidone—Nausea—Propylthiouracil—Graves' disease	0.00196	0.00819	CcSEcCtD
Ziprasidone—HRH1—eye—Graves' disease	0.00195	0.0178	CbGeAlD
Ziprasidone—HRH1—connective tissue—Graves' disease	0.00188	0.0171	CbGeAlD
Ziprasidone—ADRA1A—adipose tissue—Graves' disease	0.00187	0.017	CbGeAlD
Ziprasidone—ADRA2A—connective tissue—Graves' disease	0.00185	0.0168	CbGeAlD
Ziprasidone—DRD2—pituitary gland—Graves' disease	0.00184	0.0167	CbGeAlD
Ziprasidone—KCNH2—pituitary gland—Graves' disease	0.00181	0.0165	CbGeAlD
Ziprasidone—ADRA2C—pituitary gland—Graves' disease	0.00179	0.0162	CbGeAlD
Ziprasidone—ADRA2C—adipose tissue—Graves' disease	0.00178	0.0162	CbGeAlD
Ziprasidone—CHRM3—thyroid gland—Graves' disease	0.00176	0.016	CbGeAlD
Ziprasidone—HTR2A—eye—Graves' disease	0.00163	0.0148	CbGeAlD
Ziprasidone—HTR2A—connective tissue—Graves' disease	0.00157	0.0143	CbGeAlD
Ziprasidone—CYP3A5—adipose tissue—Graves' disease	0.00149	0.0135	CbGeAlD
Ziprasidone—HRH1—adipose tissue—Graves' disease	0.00145	0.0131	CbGeAlD
Ziprasidone—ADRA2A—pituitary gland—Graves' disease	0.00143	0.013	CbGeAlD
Ziprasidone—ADRA2A—adipose tissue—Graves' disease	0.00142	0.0129	CbGeAlD
Ziprasidone—CYP1A2—thyroid gland—Graves' disease	0.00134	0.0121	CbGeAlD
Ziprasidone—ADRA2A—thyroid gland—Graves' disease	0.00123	0.0112	CbGeAlD
Ziprasidone—HTR2A—pituitary gland—Graves' disease	0.00121	0.011	CbGeAlD
Ziprasidone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000156	0.00135	CbGpPWpGaD
Ziprasidone—SLC6A4—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000151	0.00131	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—TSHR—Graves' disease	0.000151	0.00131	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—TSHR—Graves' disease	0.00015	0.00131	CbGpPWpGaD
Ziprasidone—CHRM5—GPCR downstream signaling—TSHR—Graves' disease	0.00015	0.0013	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—TSHR—Graves' disease	0.000149	0.0013	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—TSHR—Graves' disease	0.000146	0.00127	CbGpPWpGaD
Ziprasidone—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000146	0.00127	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	0.000145	0.00126	CbGpPWpGaD
Ziprasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000145	0.00126	CbGpPWpGaD
Ziprasidone—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000145	0.00126	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—TSHR—Graves' disease	0.000144	0.00125	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—TSHR—Graves' disease	0.000143	0.00124	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling by GPCR—CXCL10—Graves' disease	0.000142	0.00124	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—TSHR—Graves' disease	0.000142	0.00123	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—TSHR—Graves' disease	0.000141	0.00122	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	0.00014	0.00122	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	0.00014	0.00121	CbGpPWpGaD
Ziprasidone—DRD5—GPCR downstream signaling—CXCL10—Graves' disease	0.000139	0.00121	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—TSHR—Graves' disease	0.000136	0.00118	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR ligand binding—CXCL10—Graves' disease	0.000136	0.00118	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	0.000134	0.00116	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TSHR—Graves' disease	0.00013	0.00113	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—TSHR—Graves' disease	0.00013	0.00113	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—TSHR—Graves' disease	0.000128	0.00111	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	0.000127	0.0011	CbGpPWpGaD
Ziprasidone—DRD5—Signaling by GPCR—CXCL10—Graves' disease	0.000126	0.00109	CbGpPWpGaD
Ziprasidone—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000125	0.00109	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—GC—Graves' disease	0.000125	0.00108	CbGpPWpGaD
Ziprasidone—DRD2—GPCR ligand binding—CXCL10—Graves' disease	0.000123	0.00107	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	0.000123	0.00107	CbGpPWpGaD
Ziprasidone—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000123	0.00107	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000122	0.00106	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	0.000122	0.00106	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—GC—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—HRH1—GPCR ligand binding—CXCL10—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR ligand binding—CXCL10—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR ligand binding—CXCL10—Graves' disease	0.00012	0.00104	CbGpPWpGaD
Ziprasidone—HTR1E—GPCR downstream signaling—IL2RA—Graves' disease	0.00012	0.00104	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	0.000119	0.00103	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—TSHR—Graves' disease	0.000119	0.00103	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	0.000119	0.00103	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	0.000117	0.00101	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	0.000116	0.001	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TSHR—Graves' disease	0.000115	0.001	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—TSHR—Graves' disease	0.000112	0.000968	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—TSHR—Graves' disease	0.000111	0.000963	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	0.00011	0.000958	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling by GPCR—IL2RA—Graves' disease	0.000109	0.000945	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—TSHR—Graves' disease	0.000108	0.000936	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—TSHR—Graves' disease	0.000108	0.000936	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—GC—Graves' disease	0.000107	0.000932	CbGpPWpGaD
Ziprasidone—HTR6—GPCR downstream signaling—CXCL10—Graves' disease	0.000107	0.00093	CbGpPWpGaD
Ziprasidone—HTR7—GPCR downstream signaling—CXCL10—Graves' disease	0.000107	0.000929	CbGpPWpGaD
Ziprasidone—HTR1D—GPCR downstream signaling—CXCL10—Graves' disease	0.000106	0.000923	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	0.000106	0.000922	CbGpPWpGaD
Ziprasidone—DRD5—GPCR downstream signaling—IL2RA—Graves' disease	0.000106	0.000921	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	0.000106	0.000921	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—TSHR—Graves' disease	0.000106	0.000919	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—TSHR—Graves' disease	0.000106	0.000916	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—TSHR—Graves' disease	0.000105	0.000913	CbGpPWpGaD
Ziprasidone—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000105	0.000912	CbGpPWpGaD
Ziprasidone—HTR1B—GPCR downstream signaling—CXCL10—Graves' disease	0.000104	0.000904	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	0.000104	0.000904	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	0.000104	0.000901	CbGpPWpGaD
Ziprasidone—DRD4—GPCR downstream signaling—CXCL10—Graves' disease	0.000102	0.000889	CbGpPWpGaD
Ziprasidone—CHRM4—GPCR downstream signaling—CXCL10—Graves' disease	0.000101	0.000878	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—IL2RA—Graves' disease	9.94e-05	0.000863	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—GC—Graves' disease	9.86e-05	0.000856	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—TSHR—Graves' disease	9.79e-05	0.00085	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—CXCL10—Graves' disease	9.73e-05	0.000845	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—CXCL10—Graves' disease	9.72e-05	0.000844	CbGpPWpGaD
Ziprasidone—CHRM5—GPCR downstream signaling—CXCL10—Graves' disease	9.68e-05	0.00084	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—CXCL10—Graves' disease	9.66e-05	0.000838	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	9.65e-05	0.000838	CbGpPWpGaD
Ziprasidone—DRD5—Signaling by GPCR—IL2RA—Graves' disease	9.64e-05	0.000836	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—TSHR—Graves' disease	9.63e-05	0.000836	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—TSHR—Graves' disease	9.61e-05	0.000834	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—TSHR—Graves' disease	9.58e-05	0.000832	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—TSHR—Graves' disease	9.55e-05	0.000829	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—B3GNT2—Graves' disease	9.47e-05	0.000822	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—CXCL10—Graves' disease	9.46e-05	0.000821	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—TSHR—Graves' disease	9.46e-05	0.000821	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	9.43e-05	0.000819	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—CXCL10—Graves' disease	9.31e-05	0.000808	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—IL2RA—Graves' disease	9.29e-05	0.000806	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—CXCL10—Graves' disease	9.23e-05	0.000801	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—B3GNT2—Graves' disease	9.2e-05	0.000798	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—CXCL10—Graves' disease	9.18e-05	0.000797	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—CXCL10—Graves' disease	9.1e-05	0.00079	CbGpPWpGaD
Ziprasidone—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	9.07e-05	0.000788	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—GC—Graves' disease	9.04e-05	0.000784	CbGpPWpGaD
Ziprasidone—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	8.91e-05	0.000773	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TSHR—Graves' disease	8.9e-05	0.000772	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TSHR—Graves' disease	8.89e-05	0.000771	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TSHR—Graves' disease	8.83e-05	0.000766	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—CXCL10—Graves' disease	8.79e-05	0.000763	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	8.76e-05	0.000761	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TSHR—Graves' disease	8.65e-05	0.00075	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TSHR—Graves' disease	8.51e-05	0.000738	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—CXCL10—Graves' disease	8.42e-05	0.000731	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TSHR—Graves' disease	8.39e-05	0.000728	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—CXCL10—Graves' disease	8.38e-05	0.000727	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—CXCL10—Graves' disease	8.27e-05	0.000717	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	8.22e-05	0.000713	CbGpPWpGaD
Ziprasidone—HTR6—GPCR downstream signaling—IL2RA—Graves' disease	8.19e-05	0.000711	CbGpPWpGaD
Ziprasidone—HTR7—GPCR downstream signaling—IL2RA—Graves' disease	8.18e-05	0.00071	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—B3GNT2—Graves' disease	8.14e-05	0.000707	CbGpPWpGaD
Ziprasidone—HTR1D—GPCR downstream signaling—IL2RA—Graves' disease	8.13e-05	0.000706	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TSHR—Graves' disease	8.04e-05	0.000698	CbGpPWpGaD
Ziprasidone—HTR1B—GPCR downstream signaling—IL2RA—Graves' disease	7.96e-05	0.000691	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	7.93e-05	0.000689	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	7.89e-05	0.000685	CbGpPWpGaD
Ziprasidone—DRD4—GPCR downstream signaling—IL2RA—Graves' disease	7.83e-05	0.00068	CbGpPWpGaD
Ziprasidone—CHRM4—GPCR downstream signaling—IL2RA—Graves' disease	7.73e-05	0.000671	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—CXCL10—Graves' disease	7.68e-05	0.000666	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TSHR—Graves' disease	7.66e-05	0.000665	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TSHR—Graves' disease	7.56e-05	0.000656	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	7.56e-05	0.000656	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—IL2RA—Graves' disease	7.54e-05	0.000655	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—B3GNT2—Graves' disease	7.47e-05	0.000648	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	7.46e-05	0.000648	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—CXCL10—Graves' disease	7.45e-05	0.000647	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL2RA—Graves' disease	7.44e-05	0.000646	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL2RA—Graves' disease	7.43e-05	0.000645	CbGpPWpGaD
Ziprasidone—CHRM5—GPCR downstream signaling—IL2RA—Graves' disease	7.4e-05	0.000642	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL2RA—Graves' disease	7.38e-05	0.000641	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL2RA—Graves' disease	7.23e-05	0.000627	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	7.21e-05	0.000625	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	7.17e-05	0.000622	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL2RA—Graves' disease	7.11e-05	0.000617	CbGpPWpGaD
Ziprasidone—DRD1—GPCR downstream signaling—IL2RA—Graves' disease	7.05e-05	0.000612	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL2RA—Graves' disease	7.02e-05	0.000609	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—CXCL10—Graves' disease	6.97e-05	0.000605	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	6.97e-05	0.000605	CbGpPWpGaD
Ziprasidone—DRD3—GPCR downstream signaling—IL2RA—Graves' disease	6.96e-05	0.000604	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	6.86e-05	0.000595	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	6.85e-05	0.000595	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—B3GNT2—Graves' disease	6.85e-05	0.000594	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—CXCL10—Graves' disease	6.84e-05	0.000594	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TSHR—Graves' disease	6.82e-05	0.000592	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—CXCL10—Graves' disease	6.82e-05	0.000592	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—CXCL10—Graves' disease	6.8e-05	0.00059	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	6.73e-05	0.000584	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL2RA—Graves' disease	6.72e-05	0.000583	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	6.71e-05	0.000582	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TSHR—Graves' disease	6.59e-05	0.000572	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TSHR—Graves' disease	6.55e-05	0.000569	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL2RA—Graves' disease	6.43e-05	0.000558	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GC—Graves' disease	6.42e-05	0.000558	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL2RA—Graves' disease	6.4e-05	0.000556	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TSHR—Graves' disease	6.37e-05	0.000553	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—CXCL10—Graves' disease	6.33e-05	0.000549	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL2RA—Graves' disease	6.32e-05	0.000548	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	6.28e-05	0.000545	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TSHR—Graves' disease	6.27e-05	0.000544	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	6.24e-05	0.000541	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	6.22e-05	0.00054	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—CXCL10—Graves' disease	6.21e-05	0.000539	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—CXCL10—Graves' disease	6.19e-05	0.000537	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—CXCL10—Graves' disease	6.17e-05	0.000536	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	6.11e-05	0.00053	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	6.1e-05	0.000529	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	6.06e-05	0.000526	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	6.03e-05	0.000524	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—IL2RA—Graves' disease	5.87e-05	0.000509	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TSHR—Graves' disease	5.78e-05	0.000502	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	5.78e-05	0.000501	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CXCL10—Graves' disease	5.75e-05	0.000499	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CXCL10—Graves' disease	5.74e-05	0.000498	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CXCL10—Graves' disease	5.71e-05	0.000495	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	5.7e-05	0.000495	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL2RA—Graves' disease	5.69e-05	0.000494	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TSHR—Graves' disease	5.69e-05	0.000494	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TSHR—Graves' disease	5.68e-05	0.000493	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	5.66e-05	0.000491	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TSHR—Graves' disease	5.66e-05	0.000491	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TSHR—Graves' disease	5.64e-05	0.00049	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CXCL10—Graves' disease	5.59e-05	0.000485	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TSHR—Graves' disease	5.59e-05	0.000485	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TSHR—Graves' disease	5.57e-05	0.000484	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	5.51e-05	0.000478	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CXCL10—Graves' disease	5.5e-05	0.000477	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	5.48e-05	0.000475	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GC—Graves' disease	5.44e-05	0.000472	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CXCL10—Graves' disease	5.42e-05	0.000471	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL2RA—Graves' disease	5.33e-05	0.000462	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	5.32e-05	0.000462	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	5.24e-05	0.000455	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	5.24e-05	0.000455	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—IL2RA—Graves' disease	5.23e-05	0.000454	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—IL2RA—Graves' disease	5.21e-05	0.000452	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CXCL10—Graves' disease	5.19e-05	0.000451	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—IL2RA—Graves' disease	5.19e-05	0.000451	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TSHR—Graves' disease	5.18e-05	0.000449	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	5.14e-05	0.000446	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	5.13e-05	0.000445	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CXCL10—Graves' disease	4.95e-05	0.00043	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CXCL10—Graves' disease	4.88e-05	0.000424	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—B3GNT2—Graves' disease	4.87e-05	0.000423	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL2RA—Graves' disease	4.84e-05	0.00042	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	4.77e-05	0.000414	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	4.76e-05	0.000413	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL2RA—Graves' disease	4.75e-05	0.000412	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL2RA—Graves' disease	4.73e-05	0.000411	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL2RA—Graves' disease	4.72e-05	0.000409	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	4.67e-05	0.000405	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	4.66e-05	0.000404	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	4.41e-05	0.000383	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL2RA—Graves' disease	4.39e-05	0.000381	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL2RA—Graves' disease	4.39e-05	0.000381	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL2RA—Graves' disease	4.36e-05	0.000379	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	4.33e-05	0.000376	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL2RA—Graves' disease	4.27e-05	0.000371	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CXCL10—Graves' disease	4.26e-05	0.000369	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CXCL10—Graves' disease	4.23e-05	0.000367	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL2RA—Graves' disease	4.2e-05	0.000365	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GC—Graves' disease	4.2e-05	0.000365	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL2RA—Graves' disease	4.15e-05	0.00036	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—B3GNT2—Graves' disease	4.12e-05	0.000358	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CXCL10—Graves' disease	4.12e-05	0.000357	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	4.05e-05	0.000352	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL2RA—Graves' disease	3.97e-05	0.000345	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL2RA—Graves' disease	3.78e-05	0.000328	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL10—Graves' disease	3.74e-05	0.000324	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL2RA—Graves' disease	3.73e-05	0.000324	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL10—Graves' disease	3.68e-05	0.000319	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL10—Graves' disease	3.67e-05	0.000318	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL10—Graves' disease	3.66e-05	0.000317	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL10—Graves' disease	3.65e-05	0.000316	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL10—Graves' disease	3.61e-05	0.000313	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	3.6e-05	0.000312	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	3.37e-05	0.000292	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	3.35e-05	0.00029	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL2RA—Graves' disease	3.25e-05	0.000282	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL2RA—Graves' disease	3.24e-05	0.000281	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—B3GNT2—Graves' disease	3.18e-05	0.000276	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL2RA—Graves' disease	3.15e-05	0.000273	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	3.1e-05	0.000269	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2RA—Graves' disease	2.86e-05	0.000248	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2RA—Graves' disease	2.81e-05	0.000244	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2RA—Graves' disease	2.8e-05	0.000243	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2RA—Graves' disease	2.8e-05	0.000243	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2RA—Graves' disease	2.79e-05	0.000242	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2RA—Graves' disease	2.76e-05	0.000239	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	2.75e-05	0.000239	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	2.56e-05	0.000222	CbGpPWpGaD
